Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study
Clinical and radiographic outcomes of posterolateral lumbar spine fusion in humans using recombinant human bone morphogenetic protein-2: an average five-year follow-up study
复制标题
DOI：
10.1007/s00264-008-0600-5
复制
发表时间：
2009-08-01
影响因子：
2.7
通讯作者：
Ishiguro, Naoki
中科院分区：
文献类型：
--
作者：
Katayama, Yoshito;Matsuyama, Yukihiro;Ishiguro, Naoki
本研究的目的是确定重组人骨形态发生蛋白-2(rhBMP-2)是否可以作为唯一的成骨刺激因子，在相同水平的腰椎后外侧融合术(PLF)中取得与自体植骨相同的成功，并描述直到骨愈合的进展。这项研究包括11名接受L4-5腰椎前路固定术的患者。右侧仅使用以聚乳酸/乙醇酸(PLGA)为载体的重组人骨形态发生蛋白-2，而左侧仅使用自体骨。术后12个月和24个月，右侧BMP组骨愈合率分别为73%和82%，自体骨组为91%。骨愈合率在统计学上没有显著差异。重组人骨形态发生蛋白-2可以作为唯一的成骨来源，成功地相当于PLF的自体移植。
The objectives of this study were to determine whether recombinant human bone morphogenetic protein-2 (rhBMP-2) can be used as the sole stimulator of osteogenesis with success equal to an autologous graft in posterolateral lumbar fusion (PLF) at the same level and to describe the progress until bone union. This study included 11 patients who underwent PLF of L4-5. On the right side, only rhBMP-2, for which polylactic/glycolic acid (PLGA) was used as a carrier, was used, whereas, on the left side, autogenous bone was used. The bone union rate was 73 and 82% at 12 and 24 months after surgery, respectively, on the right BMP side, while the rate on the autogenous bone side was 91%. There was no statistically significant difference in the bone union rate. rhBMP-2 can be used as the sole source of osteogenesis with success equivalent to an autologous graft of the PLF.